Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Seeking Alpha
Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Presentation Etzer Darout Barclays Bank PLC, Research Division Hello again, everyone. I'm Etzer Darout, senior biotech analyst at Barclays. It's my pleasure to welcome Protagonist Therapeutics to our fireside. With me today, I have Dinesh Patel, the Chief Executive Officer and President at Protagonist. Dinesh, maybe just to start off, for those maybe less familiar with the story, if you could just provide an overview of Protagonist, and then we'll move into Q&A. Dinesh Patel CEO, President, Secretary & Director Sounds like a plan. First and foremost, thanks for inviting us. And I have to mention that this does take me down memory lane. Protagonist, we did our IPO back in 2016, and Barclays was one of the bank that helped us achieve that component of going public. So thanks for that as well to Barclays. So yes, right from the get-go,
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- J&J Expands New Drug Portfolio With Icotyde's FDA Approval [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (PTGX) had its price target raised by Leerink Partners from $107.00 to $110.00. They now have an "outperform" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by JPMorgan Chase & Co. from $95.00 to $106.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $115.00 to $125.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $113.00 to $119.00. They now have an "overweight" rating on the stock.MarketBeat
PTGX
Earnings
- 2/25/26 - Miss
PTGX
Sec Filings
- 3/24/26 - Form 144
- 2/25/26 - Form S-8
- 2/25/26 - Form 10-K
- PTGX's page on the SEC website